INTRODUCTION
Large granular lymphocyte (LGL) disorders are characterized by the chronic proliferation of cytotoxic lymphocytes. These LGL expansions can be sustained by two distinct subpopulations, CD3+ cytotoxic T lymphocytes (CTLs) or CD3-natural killer (NK) cells. 1, 2 According to the specific involved lymphoid cell, the 2008 World Health Organization (WHO) classified chronic
LGL disorders as T-Large Granular Lymphocytic Leukemia (T-LGLL), and Chronic
Lymphoproliferative Disorder of NK Cells (CLPD-NK). 3, 4 Both diseases are characterized by abnormal expansion of cytotoxic clonal populations; in T-LGLL the marker of clonality is represented by the rearrangement of TCRγ whereas a restricted pattern of Killer Immunoglobulinlike Receptor (KIR) expression has been used as a surrogate of clonality in CLPD-NK, NK cells lacking a clonotypic structure. 2, 5 In recent years progress has been made in understanding the pathogenetic events that sustain T-LGL leukemia and CLPD-NK. 6 The identification of specific mechanisms and biological differences of neoplastic NK and T clones seem to strengthen the sub classification of these disorders made by WHO. In CLPD-NK the pathogenetic mechanism is intrinsically nested in a genetic background which determines a biased response of cytotoxic NK cells equipped with activating NK receptors, 7, 8 this pattern being mainly related to the reduced expression of other activating receptors, such as natural cytotoxic receptors. This impaired expression of inhibitory receptors is dependent on patients' genotype, characterized by the presence of multiple activating KIR genes 9 and on a discrete silencing of inhibitory KIR genes through their promoter methylation. 10 On the other hand, a crucial role for inflammatory cytokines has been clamed to understand the pathogenesis of T-
LGLL. Leukemic T-LGLs fail to undergo activation-induced cell death (AICD), this event being consequent to a critical impairment of Fas-induced apoptosis. 11, 12 The etiology of LGL expansions is largely unknown. This is due to the fact that not a single, specific agent is responsible of the LGL proliferation, which is likely the expression of an abnormal processing of different foreign antigens. Several data suggest the concept that different events induce the disease through a pathogenic mechanism that is common for both disorders. In this regard, a number of reports strongly support the role of a chronic/persistent antigenic stimulation provided by an auto-antigen or a foreign infectious antigen. [13] [14] [15] [16] [17] This would lead to the expansion of a fully differentiated effector cytotoxic LGL which is not eliminated as a consequence of an impairment of apoptotic pathways and persistence of chemokines triggering a chronic stimulation. 12 The phenomenon of clonal drift, i.e. the change of dominant T cell clone in nearly 50% of LGLL patients, has been interpreted in line with this hypothesis. 18 Similarly, in both disorders an in vivo activation of STAT3 and the presence of somatic STAT3 mutations have been observed. [19] [20] [21] [22] The identification that STAT3 SH2 somatic mutations can be found with a similar frequency either in NK or T cell disorders further indicates that a common mechanism is responsible for the pathogenesis of both disorders, possibly driven by a shared genetic lesion irrespective of the cell lineage.
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With this as a background, we hypothesized that the antigenic pressure favouring NK cell proliferation in CLPD-NK would represent a relevant signal also for the T compartment, ultimately leading to the expansion of cytotoxic clonal T cell populations. To investigate this hypothesis, we analyzed the rearrangement of TCRγ in the residual "normal" T lymphocytes in 48 patients with CLPD-NK. Our data show that in a half of these patients a clonal T cell population was detectable at the time of diagnosis, whereas in 27% of our cohort of patients, it also occurred during the follow up. In some cases this phenomenon leads to a switch from a KIR restricted CLPD-NK to a monoclonal T-LGLL, strengthening the suggestion that a common mechanism takes place in these chronic LGL disorders.
METHODS

Patients
Forty eight patients were enrolled in this study. All patients were affected by CLPD-NK, characterized by a chronic proliferation of CD16+/CD3-NK cells. Diagnoses were made according to reported criteria. 5, 23, 24 At the time of the enrolment, none of the patients had received treatment.
Twenty-nine patients were available for serial measurements over an extended period (3 to 14 years 
Flow cytometry analysis
Peripheral blood sample collection from patients was performed at clinically testing as detailed in supplemental materials.
PCR analysis for TCRγ clonality and STAT3 mutationsStatistical analysis
The comparison of characteristics between patients with monoclonal and polyclonal TCRγ rearrangement was performed using "Student's t-test"; p < 0.05 or p < 0.01 were accepted as statistically significant.
Study approval
Patients' samples and clinical features were collected from the Hematology Division of the Department of Medicine in accordance with a protocol approved by the Institutional Review Board for experimental studies (Protocol # 2362P, approved on July 6, 2011). Written informed consent was obtained in accordance with the Declaration of Helsinki.
RESULTS
Patient characteristics
We have collected a well annotated cohort (n=48) of patients with CLPD-NK ( Figure 1A ). More specifically, 4 patients (9%) presented a restricted expression of CD158a (KIR2D1), 10 patients (21%) presented the CD158b (KIR2DL2/3 and KIR2DS2), 5 patients (10%) presented the CD158i (KIR2DS4), and 5 patients (10%) presented the CD158e (KIR3D1). There were also 3 patients (6%) with the restriction of both CD158a and CD158b. Finally, 21 patients (44%) were characterized by the lack of KIR expression on cell surface. Analysis of NK activity at the time of diagnosis showed that all cases were characterized by the ability to induce a strong cytolytic response (data not shown).
Rearrangement of the TCRγ gene in residual T CD3+ population in CLPD-NK patients
Detection of rearrangements of the T-cell receptor (Table 1 Supplemental). Finally, since clonal T cell populations with a characteristic CD8+, CD28-, CD57-phenotype have been reported to be detectable over 65 years of age in normal individuals, 29 in six patients the expanded CD3+/CD57+ population was sorted and TCRγ rearrangement was analyzed in these cells, confirming the monoclonal nature of this abnormal cell subset (data not shown).
STAT3 mutations in NK cells
Somatic STAT3 mutations at diagnosis were demonstrated in 4 patients out of 48 studied, Y640F in 2 cases and D661Y in 2 cases. In all these cases the data were also confirmed when purified NK cells were used for the analysis. In 5 patients, we investigated the presence of STAT3 mutations at different times along the follow up of disorder (range 3 to 14 years). In patient #21, rearranged
TCRγ was detected already at diagnosis, whereas in patients #15, 18, 31 and 35 rearrangement appeared during follow up. In all these patients STAT3 mutations were not found neither at diagnosis nor during the follow up.
Clonotypic dynamics and disease progression
In 29 patients, the presence of a clonal T cell population was investigated during an extended period of follow up ranging from 3 to 14 years. Analysis of TCR gene rearrangement at different year intervals allowed the identification of different patterns of T cell clonal population behaviour during the course of the disease. Among these 29 patients, in 9 patients (31%) we never observed a T cell clonal population, even after several years (range 3 to 14 years) from diagnosis. In 13 patients (45%) the TCRγ rearrangement, detectable already at diagnosis, was persistent during years of follow up. In 7 patients (24%) the TCRγ rearrangement appeared after few years from diagnosis.
Interestingly, whereas in some patients a shift from a polyclonal to a monoclonal T cell population was documented, none of the patients with a initial clonal TCR recovered to a normal polyclonal TCR repertoire.
Analysis of NK CD16+/CD3-and T CD3+ population in CLPD-NK patients during the course of disease
The observation that T cell clones were detected in near half of CLPD-NK and that some patients Figure 2D ). Interestingly, all these cases were characterized by a shift from a KIR restricted NK expansion to a T CD3+/CD57+ abnormal population, with monoclonal TCR rearrangement (Table 3) . Moreover, at the last follow up, the initial KIR restricted population was still documented in five of these cases (# 15, 17, 18, 20, 45) , whereas in two patients a disappearance of KIR restricted population was shown, with normalization of NK cell subsets (# 31 and 35, Table 3 ). Patients # 21, instead, presented already at diagnosis a monoclonal T CD3+/CD57+ cell population (# 21, Figure   2D ), which persisted during the follow up, with a concomitant decrease of NK cells population characterized by a shift from a KIR restricted NK expansion to a normal KIR repertoire. Finally, the only patient in group B in whom a monoclonal TCRγ rearrangement was never found (# 46, Figure   2D ) achieved hematologic remission paralleled by gradual disappearing of the aberrant NK population, increased number to normal value of a T CD3+/CD57-/CD16-cell population with polyclonal TCR and normal CD4/CD8 ratio, suggesting a spontaneous remission of CLPD-NK (Table 3) .
TCR Vβ usage in CLPD-NK patients
TCR Vβ clonotyping was available in 6 patients with 6 years mean follow up (range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . In LGL leukemia. Clemente et al suggested that the clonal drift is a discrete characteristic of the disease in its early manifestation.
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Clinical behaviour
The primary hematological manifestation was neutropenia (<1,500/μl; 27% of patients) never reaching the level of severe neutropenia, followed by anemia (<10 gr/dl; 8%), and trombocytopenia (<100,000/mm 3 ; 6% of patients). Associated diseases were reported in 15 cases (polymialgia 2 cases, polymyositis 3 cases, Non Hodgkin lymphoma 1 case, MGUS 2 cases, HCV infection 1 case, HBV infection 1 case, prostate cancer 1 case, sarcoidosis 1 case, thyroiditis 1 case, essential thrombocytemia 2 cases). All patients were found to be positive for EBV and CMV IgG antibodies.
One patient underwent splenectomy for not defined reasons several years before CLPD-NK diagnosis. Nine patients needed treatment, due to associated diseases rather than for CLPD-NK. In particular, two patients for each group were under low dose methotrexate for autoimmune disorders.
Concerning patients with and without a monoclonal T population, no differences were demonstrated between the groups, except that patients with TCRγ clonal rearrangement had a median age of 56 years (range 25-77) with respect to the other group of patients who had a median age of 65 years (range 44-86, Student's t test, *p=0.012, Table 2 ). No clinical differences were also demonstrated in patients shifting from NK to T LGL proliferation.
DISCUSSION
Our results demonstrated the presence of monoclonal T cell populations in 48% of cases in this large cohort of patients with CLPD-NK. Even more intriguing is the finding that these monoclonal populations can be detected not only at the time of diagnosis, but in some cases they can occur during the natural history of disease, indicating that the association of T and NK proliferations is much more frequent that initially thought. The T cell clone can eventually became so relevant to be dominant, leading to the shift from CLPD-NK to T-LGLL. This concept supports the hypothesis that the immunological reaction ongoing in patients with CLPD-NK, is able to sustain the clonal expansion of both types of cells, NK and T. In this contest, it is likely that CLPD-NK and T-LGLL should not be viewed as separated entities, but should be considered as the different sides of the same disorder, with a common pathogenic mechanism.
This hypothesis is apparently in contrast with the 2008 WHO that classifies CLPD-NK and T-LGLL as two different diseases. 3, 4 However, the WHO classification relies on different lineage features of T and NK cells, not taking into account putative common pathogenic mechanisms and clinical features. As a matter of fact, chronic NK and T cell expansions display a similar morphology and, on clinical grounds, in both types of patients cytopenia and other co morbidities are often associated, including autoimmune conditions and/or malignancies. 30, 31 Furthermore, the treatment is very similar in CLPD-NK and T-LGLL patients, entailing an immunosuppressive regimen or careful observation of chronic lymphocytosis. 1 The identification of patients with a NK population bearing a restricted KIR expression and an accompanying CD3+/CD57+ clonal T cell population(s) herein demonstrated questions the accuracy of this subdivision, also considering that patients with or without clones lack clinical differences.
The etiopathogenesis of these disorders is not completely understood, in particular for CLPD-NK. In these latter, several experimental data support the involvement of a genetic background. In fact, NK cells equipped with an activating KIR gene aplotype are thought to be more prone to clonal expansion, with a concomitant marked silencing of inhibitory KIRs. 9, 10, 32 The selection of T cells during the T-LGLL pathogenesis has been more precisely investigated. T-LGL cells exhibit the activation of multiple survival signaling pathways, 33 are characterized by the failure to undergo AICD (11), and are not sensitive to Fas-induced apoptosis. 12 Although CLPD-NK and T-LGLL seem different, the steps that take place during their etiopathogenesis are similar. In fact, a number of reports strongly support the role of a chronic/persistent antigenic stimulation by an autoantigen or a foreign infectious antigen as the initial step. [13] [14] [15] [16] [17] Since disorders of large granular lymphocytes are often associated to an inflammatory background, it is likely that the chronic stimulation that triggers the clonal expansion of NK cells during the pathogenesis and progression of CLPD-NK is also able to sustain the expansion of the T population characterized by a TCRγ monoclonal rearrangement. Antigens and cytokines involved in this process have already been matter of investigation, IL-2 and IL-15 being well known cytokines that regulate biology of NK and T cells and both have been claimed to be involved in LGL clonal expansion. [34] [35] [36] A pivotal role is also played by the JAK/STAT pathway, an over-expression and over-activation of STAT3 by IL-6 being responsible for the survival of neoplastic T clone. 20 Furthermore, somatic mutations of STAT3 are crucial in both T-LGLL and CLPD-NK, as recently reported. 21, 22 The relevant role of STAT family genes in the pathogenesis of LGL has been recently reinforced by the demonstration that STAT5b mutations can be detected, although at a very low frequency (4 out of 211 cases), in patients with LGL proliferations. 37 The frequency of mutated STAT3 in our cohort of patients is lower with respect to the frequency reported by other. 21, 22, 38, 39 Different study populations can be taken into consideration to explain the different results. In particular, the more indolent clinical features of our patients as compared with those reported by Koskela et al 21 represent a plausible explanation. As a matter of facts, a recent paper by Clemente et al, 40 shows a lower incidence of STAT3 mutation than that reported by the same group in a previous cohort. 22 Finally, the suggestion that STAT3 mutation might occur in a common T/Natural Killer (NK) cell precursor 41 Our results support the concept that the mechanism accounting for the proliferation of pathological NK and T clones could be common for CLPD-NK and T-LGLL. This hypothesis is supported by the presence of both NK and T clones at the time of the diagnosis in a high number of cases, and by the evidence that clonal T rearrangements can occur after years from diagnosis, both clones persisting in some cases during the natural history of disorder. By flow cytometry, in nearly 50% of patients with T-LGLL studied, Clemente et al reported the phenomenon recognized as clonal drift in the Vβ usage. 18 The above Authors observed that the clone size was smaller in the clonal drift group with respect to stable patients, supporting the concept that we are dealing with a disease in its early manifestation. CDR3 AA sequence was also shown to maintain unaltered in stable clones, whereas expansions with different Vβ restriction presented marked different CDR3
sequences, suggesting that clonal drift was not associated with a conserved TCRγ homology. We extended this observation describing patients in whom a clonal switch takes place, from a KIR restricted NK population to a dominant T monoclonal population, with no longer demonstration in some cases of the initial NK clonal population. We also presented data on a patient who underwent a complete recovery of the disorder, with normal NK and T cell values, a not restricted KIR expression cellular pattern and polyclonal TCRγ rearrangement. The possibility of a complete recovery of CLPD-NK or T-LGLL, has already been previously reported. 42, 43 Taken together, these data are consistent with the suggestion that the putative inciting factors accounting for these disorders still persist for many years and possibly for the lifelong of patients. This implies that i) a long lasting follow up of these patients is required, and ii) the possibility of worsening of clinical features even in indolent cases could never be ruled out, as reported in the literature. 44, 45 Our data add a significant field of knowledge on chronic T and NK lymphoproliferative diseases. Since a common event is likely to trigger clonal expansion in both disorders, further studies are needed to investigate the factors driving both NK and T clonal expansions.
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MATERIALS AND METHODS
Flow cytometry analysis
The collection of peripheral blood samples from patients was performed during medical examination.
Peripheral LGLs. Briefly, cells were stained with the appropriate mAbs either unlabeled or labeled; staining with unlabeled mAb was followed by PE-or FITC-conjugated isotype-specific goat anti mouse second reagent (Southern Biotechnology, Birmingham, AL, or Caltag, Burlingame, CA). A PE-Cy5 CD16/APC CD3 gate was set and the status of the antigens of interest was analyzed only on CD16+/CD3-, CD16+/CD3+ or CD57+/CD3+ gated cells. Stained cells were scored using a
FACSCcanto analyzer (Becton Dickinson). 15,000 events were analyzed and data were processed using CELLQuest PRO software (Becton Dickinson).
PCR analysis for TCRγ clonality and STAT3 mutations
TCRγ gene rearrangement analysis was performed in all the patients using PCR analysis as already reported. 24 Briefly, PCR was carried out on DNA purified by PBMCs or CD3+/CD57+ cells of patients. Primers specific for the variable region of the rearranged TCRγ chain gene were used as two mixes: mix I (Set I primers), which contained TCRγV 2, 3, 4, 8, and 9; and mix II (Set II primers) which contained TCRγV 5, 10, 11, and 12. For the J segments, three primers were included: JGT12 for J1.3 and J2.3, JGT3 for J1.1 and J1.2, and JGT4 for J1.2. PCR products were considered monoclonal only if at least one discrete band within the expected size range (clonal bands ranged from 170 to 230 bp) was amplified and observed on agarose gel electrophoresis.
Twenty-nine patients were available for at least two (from 2 up to 5) measurements over 3 to 14 years.
T Cell Receptor Beta Variable (Vβ) region repertoire expression was performed, as already reported, [25] [26] [27] [28] in 6 patients over 3-14 years follow up. Briefly, RNA was purified from PBMCs of patients and transcribed into cDNA. Detection of TCRγ repertoire restriction was performed by PCR using Vβ family (from 1 to 24) -specific primers. The amplified products were separated on 2% agarose gel electrophoresis (Vβ bands ranged from 170 to 220 bp). Agarose gels were acquired with the CHEMI DOC XRS supply (Bio-Rad Laboratories; Milan, Italy).
Analysis of D661V, D661Y, D661H, Y640F, N647I and K658N STAT3 mutations were performed according to previously reported methods 21 on DNA from purified NK or PBMCs. As healthy control, DNA from both CD16+/CD3-cells and PBMCs of buffy coats was used. DNA was sequenced as previously reported. 20 The presence of D661Y and Y640F mutations non-detectable by direct sequencing, due to the low sensitivity of the method (reaching 25% of positive cells) was also analyzed by a DNA tetra-primer amplification refractory mutation system assay (ARMS-PCR), as reported. ARMS-PCR allows to identify STAT3 mutations in the pathologic clone with a sensitivity of less than 10% of mutated cells.
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Investigation on sensitivity of PCR analysis for TCRγ clonality
To investigate the sensibility of PCR analysis for TCRγ clonality, we performed PCR using DNA purified by a monoclonal CD57+ population with rearranged TCRγ. DNA was serially diluted with DNA purified by CD3+ population with polyclonal TCRγ. We used 200ng of total DNA in each
